Global evaluation study for recent axial spondyloarthritis
Part of Bones, joints & muscles clinical trials.
This study is for people recently diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It tests whether a standardized global review and education program can help patients better understand and manage their condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult under 80 years old.
- You have been diagnosed with axial spondyloarthritis by a rheumatologist within the past 12 months.
- You have not already taken part in or planned to take part in a similar education program for your disease in the next year.
- You do not have a condition like major depression or substance use that could affect your ability to participate.
- You are able to complete all study activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
This study follows people who were diagnosed with axial spondyloarthritis (axSpA) recently to better understand the condition over time. It’s mainly for adults and teens who can consent and can communicate in English.
This study looks at people who have just been diagnosed with a type of arthritis that affects the spine (axial spondyloarthritis) and have not yet started treatment. The goal is to understand the disease better.
This study aims to confirm new classification criteria for axial spondyloarthritis, a type of inflammatory arthritis affecting the spine and sacroiliac joints. Participants with chronic back pain lasting at least 3 months and starting before age 45 will undergo a series of tests to see if these new criteria better identify the condition.
This trial tests a new oral medication that may reduce inflammation and improve symptoms in people with axial spondyloarthritis. It is in early phases, meaning the drug is still being studied for safety and effectiveness.
This study follows people recently diagnosed with spondyloarthritis (a type of inflammatory arthritis) to understand how the disease changes over time. It aims to improve early detection and treatment.
Hear when a new Axial Spondylarthritis (axSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.